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Summary. The effects of glucocorticoids administered in 
vivo and in vitro on lectin-induced proliferation of lympho- 
cytes sampled from venous blood were investigated in 
patients with atopic dermatitis (AD) and in normal con- 
trois. Stimulation by concanavalin A (Con A), phytohaem- 
agglutinin A (PHA) and pokeweed mitogen (PWM) in 
patients and controls did not differ significantly under base- 
line conditions. After in vivo administration of methylpred- 
nisolone the decline of Con A-induced blastogenesis of leu- 
cocytes was similar in both groups, whereas PHA stimu- 
lation caused a significant reduction in the controls only. 
In vitro addition of different dexamethasone concentrations 
had a pronounced suppressive ffect on Con A- and PHA- 
induced blastogenesis in both groups, whereas PWM stimu- 
lation was unaffected. Pretreatment in vivo with 
methylprednisolone further decreased the suppression of 
the Con A and PHA lymphocyte proliferation rate by 
dexamethasone added in vitro in controls but not in 
patients. With regard to B-cell proliferation generated by 
PWM, no consistent glucocorticoid effect could be ob- 
served. The impaired effect on lymphocyte blastogenesis of 
glucocorticoids administered in vivo, in contrast o a normal 
in vitro reaction to dexamethasone, together with recent 
findings of an altered glucocorticoid receptor pharma- 
cology in AD, points to a decreased biological in vivo 
efficiency of methylprednisolone in atopic dermatitis. 
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Atopic dermatitis (AD) is accompanied by a variety of 
disturbed immune [19, 25, 29], hormonal [17, 21] and 
even psychological [11] factors. In particular, a decrease 
in suppressors cells [1, 22] as well as normal rates of B 
lymphocytes have been noted [26, 30, 32]. However, some 
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authors have reported normal T cells and elevated B cells 
in atopic dermatitis [6, 12]. 
Results of studies evaluating lymphocyte response in 
AD patients to different mitogens are variable. Hypo- 
responsiveness of T- and B-cell proliferation following 
stimulation with pokeweed mitogen (PWM), concana- 
valin A (Con A) or phytohaemagglutinin A (PHA) [5, 18, 
20, 26, 29] has been reported as well as normal Con A-, 
PHA- and PWM-induced lymphocyte blastogenesis [13, 
23, 32]. Glucocorticoids inhibit lymphocyte proliferation 
[8, 28] by cytokinetic mechanisms [24] and affect the 
number of subpopulations of circulating lymphocytes by 
inducing a redistribution of intravasal cells to other 
lymphoid compartments, e.g. to the bone marrow [8, 9]. 
Moreover, glucocorticoids have been shown to inhibit 
interleukin-1 (IL-I) [31] and interleukin-2 (IL-2) [4] pro- 
duction leading to impaired lectin-induced blastogenesis 
[8, 18]. T-cell proliferation generated by Con A [8, 10] 
and PHA [8, 16, 34] is suppressible by glucocorticoids in
vivo and in vitro. However, PWM induced B-cell prolifer- 
ation is relatively resistant to glucocorticoids [2, 15]. 
In view of the numerous effects of glucocorticoids on 
the immune system and their frequent use in the treatment 
of AD, the present study was designed to evaluate the 
effect of glucocorticoids, administered in vivo and in 
vitro, on the characteristics of lymphocyte proliferation 
under lectin-stimulated conditions in AD compared with 
healthy controls. 
Materials and methods 
Subjects 
Hospitalized patients (3 men and 8 women) suffering from AD and 
healthy controls (3 men, 7 women), with no history of asthma, hay 
fever or AD, participated in the study on a voluntary basis having 
given informed consent. Their mean age was 22.2 _+ 5.4 years and 
24.3 + 3.7 years, respectively. All participants were withdrawn from 
any systemic therapy with corticoids or ACTH at least 2 months 
prior to the study. Medication, if any, with beta-blocking and/or 
sleep-inducing drugs was stopped at least 3 days before ntering the 
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lymphocyte proliferation on days 1 and 8, blood samples were 
collected into prechilled plastic tubes containing EDTA. 
Chemicals 
3H-Thymidine (specific activity 25 Ci/mmol) was purchased from 
Amersham (Buckinghamshire, UK) and phosphate buffered saline 
(PBS) from Boehringer (Mannheim, FRG). Con A, PHA, PWM 
and sodium metrizoate-Ficoll were obtained from Sigma (St. Louis, 
Mo., USA), and Rotiszint 22 from Roth (Karlsruhe, FRG). The 
culture medium consisted of RPMI medium (Boehringer, Mann- 
heim, FRG) containing 2 mM L-glutamate (Biochrom, Berlin, 
FRG) and 0.1 mg/ml gentamicin (Biochrom) with 8% fetal calf 
serum (Biochrom) added. 
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Fig. 1. Mean dose-  response curves and AUC for Con A-generated 
lymphocyte proliferation i patients with AD and in normal controls 
under baseline conditions (m) and methylprednisolone tr atment 
(A). SEM are omitted for reasons of presentation. The inset shows 
the mean _ SEM AUC for the baseline (BASELINE) and steroid- 
treated (CORT) condition in ~tg/ml. The difference between baseline 
and methylprednisolone tr atment is significant (p < 0.04) in both 
patients and controls 
study. Cutaneous lesions of AD were treated only with corticoid- 
free ointments for at least 1 week prior to and during the study. 
Exclusion criteria were prevalence of severe internal illness, and 
alcohol, drug or nicotine abuse. Diagnosis of AD was based on a 
history of recurrent flexural eczema, a personal and/or family his- 
tory of atopy, and clinical criteria of AD as stated by Hanifin and 
Rajka [14]. Cutaneous involvement, scored according to Costa et 
al. [7], in the range moderate to marked severity, was 37-67 points 
(mean_+SD: 46.9_+10.2) before therapy and 11-55 points 
(mean +_ SD: 27.6 • 12.3) at the end of the study. 
Testprotocol 
Venous blood samples were taken at 7 a.m. and 4 p.m. into EDTA- 
containing plastic tubes on day 1. At 11 p.m. of the same day all 
patients and controls underwent a i mg dexamethasone suppression 
test to evaluate the integrity of the feedback regulation of the hypo- 
thalamus-pituitary-adrenal  axis. Post-dexamethasone blood 
samples were drawn on day 2 as described for day 1. This procedure 
was followed by daily oral methylprednisolone administration i
both groups at 7 a. m. : 8 mg on days 3 to 6, and 4 mg on days 7 and 
8. On day 8 blood was drawn at 4 p.m. For determination of
Preparation of cells 
A mononuclear cell fraction was prepared under sterile conditions 
by sodium metrizoate-Ficoll density-gradient centrifugation [3]. 
Cells were washed twice in 40 ml PBS for 10 rain and incubated 
for 60 min at 37~ to allow sufficient dissociation of endogenous 
hormone, followed by a third washing procedure. The final concen- 
tration of cells was determined using a Coulter Counter (Model $5, 
Coulter Electronics, UK). The viability of the cells exceeded 95% 
as judged from their ability to exclude trypan blue. Contamination 
by erythrocytes was < 10%, and by granulocytes and monocytes 
< 8%, and did not differ between the test days. 
Lymphocyte proliferation tests 
Lymphocyte proliferation experiments were performed using plastic 
microtitre plates with a total volume of 0.22 ml. Cells (25000) were 
incubated in culture medium at 37~ in an atmosphere containing 
5% COa for 60 h to evaluate Con A- and PHA-generated T-cell 
mitogenesis, and for 3i30 h to evaluate PWM-generated B-cell pro- 
liferation as well as glucocorticoid-induced inhibition of spon- 
taneous mitogenesis. Concentrations of Con A and PWM of 0.5, 1, 
5, 10, 20, 40, and 50 p~g/ml were used to evaluate the dose-response 
curves, and concentrations of 0.1, 0.5, 1, 2.5, 5, 10, and 20 ~tg/ml 
PHA were used for the determination f the effects on lymphocyte 
proliferation. In vitro glucocorticoid effects on mitogen-stimulated 
lymphocyte proliferation were assessed by increasing 
dexamethasone (DEX) concentrations from 10- ~o to 10-6 M. For 
determination of glucocorticoid effects in vitro, dose-response 
curves were obtained for concentrations of 1, 5, 10, and 40 pg/ml 
Con A and PWM, and for concentrations of 0.5, l, 5, and 10 ~tg/ml 
PHA. 
Five hours before ending the incubation period 0.5 gCi 3H- 
thymidine was added, and incorporated 3H-thymidine was sub- 
sequently separated from free nucleotide by rapid filtration through 
Whatman GF/B filters (Nr. 11731) with a Titertek cell harvester by 
washing with distilled water for 11 s at room temperature. The filters 
were transferred into plastic vials and, after the addition of 5 ml of a 
toluene-based scintillation cocktail (Rotiszint 22 Karlsruhe, FRG), 
were monitored for tritium in a Beckman LS 5000 TD beta-counter 
(Munich, FRG) (efficiency about 54%). All samples were assayed 
in triplicate with a variation coefficient of < 15%. 
Data analysis 
Lymphocyte proliferation was expressed in terms of a stimulation 
index determined from the ratio of stimulated to unstimulated (base- 
line) disintegrations per minute. The area under the dose-  response 
curves (AUC) (stimulation i dex x lectin concentration) was deter- 
mined using trapezoidal integration (unit: ~tg/ml). 
AUC PWM 
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Fig. 2. Mean dose-response curves and AUC of PWM-generated 
lymphocyte proliferation in patients and controls under baseline 
conditions (B) and methylprednisolone tr atment (A). SEM are 
omitted for reasons of presentation9 The inset shows the mean 
_+ SEM AUC for the baseline (BASELINE) and methylpredniso- 
lone treated (CORT) conditions in gg/ml. There is no significant 
difference in the reaction to methylprednisolone tr atment in 
patients and controls 
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Fig. 3. Mean dose-response curves and AUC of PHA-generated 
lymphocyte proliferation in patients and controls under baseline 
conditions (11) and methylprednisolone tr atment (A). SEM are 
omitted for reasons of presentation9 The inset shows the 
mean __ SEM AUC for the baseline (BASELINE) and methyl- 
prednisolone treated (CORT) condition in gg/ml. Baseline and 
methylprednisolone conditions differ significantly in controls only 
The results are expressed as means __ SD, and as means +_ SE in 
the figures. Comparisons between patients and controls were made 
using Student's t-test, the intra-individual comparisons by the t-test 
for paired samples. All significance l vels are two-tailed. Statistical 
significance was taken as p < 0.05. 
Results 
Increasing concentrations ofmitogens added to lympho- 
cytes from patients and controls resulted in dose-re-  
sponse curves with maximal stimulation of lymphocyte 
proliferation at 10 gg/ml Con A (Fig. 1) and at 1 gg/ml 
PWM (Fig. 2). PHA-generated mitogenesis was maximal 
at concentrations of 10-20 gg/ml (Fig. 3). There was 
no shift of the maxima in the dose-response curves in 
patients and controls after glucocorticoid administration 
(Figs. 1 -  3). The AUC after stimulation with Con A, 
PHA or PWM did not differ significantly between 
patients and controls (Figs. 1 -  3) under baseline con- 
ditions. 
Systemic glucocorticoid administration resulted in a 
significant reduction in Con A-induced blastogenesis 
(AUCco,A) in both groups (p < 0.04) (Fig. 1), whereas 
PHA-stimulation of lymphocytes resulted in a significant 
reduction in blastogenesis (AUCpHA) after glucocorticoid 
administration i  the controls only (p < 0.03) (Fig. 3). 
The differences in AUCpwM in patients and controls prior 
to and after glucocorticoid treatment did not reach sta- 
tistical significance (Fig. 2). 
Dexamethasone administered in vitro had a pro- 
nounced suppressive effect on Con A and PHA dose-  
response curves in patients and controls at baseline and 
under corticoid treated conditions (Fig. 4a, b). However, 
in vivo pretreatment with methylprednisolone further de- 
creased the in vitro suppression of AUCconA and AUCpH A 
by dexamethasone i  the controls (p < 0.05), but not in 
the patients (Fig. 4 a, b). In contrast, no consistent effect 
of the corticoid pretreatment on the in vitro response to 
dexamethasone could be observed with regard to PWM- 
generated B-cell proliferation (Fig. 4c). 
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Fig. 4a-e. Mitogen stimulation after administration f different 
dexamethasone (DEX) concentrations i  vitro in untreated (solid 
bars) and corticoid-treated (hatched bars) patients and controls, a
Mean __ SEM AUC of Con A-generated lymphocyte proliferation 
in gg/ml. A significantly greater suppression occurred in controls 
than in patients after methylprednisolone pr treatment, b Mean 
_+ SEM AUC of PHA-generated lymphocyte proliferation i gg/ml. 
A significantly greater suppression occurred in controls than in 
patients after methylprednisolone pr treatment, e Mean + SEM 
AUC of PWM-generated lymphocyte proliferation i  lag/ml. No 
significant effect of methylprednisolone pretreatment was found in 
patients and controls 
Discussion 
The normal response to Con A, PHA and PWM found 
in our patients with AD is in accordance with previous 
reports [23, 32] which could not confirm findings of 
impaired leucocyte proliferation in AD [5, 18, 20]. The 
decreased Con A-induced blastogenesis in patients and 
controls after the administration of glucocorticoids in 
vivo and in vitro may be due to the suppressive effects of 
glucocorticoids on T-cell mitogenesis [8, 16, 28, 34]. 
Corticosteroid effects on PHA-induced blastogenic re- 
sponse have been found to be variable [8]. This variability 
has been explained by the observation that 
glucocorticoids can shift the peak of the PHA dose-  
response curve to higher concentrations [8], but this could 
not be confirmed in the present study. Since the sup- 
pression of PHA responsiveness by glucocorticoids i
dose related, it could be hypothesized that the sup- 
pression only in the controls of AUCpnA after methyl- 
prednisolone therapy is due to a higher sensitivity of 
normal ymphocytes to glucocorticoids. This hypothesis 
is supported by the observation that higher gluco- 
corticoid concentrations, asobtained in vitro, also prod- 
uced a sufficient suppression of AUCpHA in patients. 
Thus, the significantly greater suppression of Con A- and 
PHA-induced blastogenesis in vitro in the controls after 
methylprednisolone tr atment points to a subtle in vivo 
resistance of leucocytes to glucocorticoids in patients with 
AD. 
Elevated IL-2 receptor levels in AD have recently been 
described [4] and glucocorticoids are known to reduce 
both IL-2 receptor sites and IL-2 production. [4, 33]. 
Therefore, impaired suppression of these receptors by 
glucocorticoids in AD may be the reason for the higher 
lectin-induced proliferation rate of lymphocytes follow- 
ing glucocorticoid therapy in comparison with the con- 
trols. 
PWM-induced blastogenesis measured after 5 days of 
culture has been shown mainly to reflect B-cell prolifer- 
ation [2, 8, 15] and has been observed to be relatively 
refractory to the suppressive effect of glucocorticoids [2, 
8, 15]. These findings are in accordance with our results 
in patients and controls. Our data show a lowered sup- 
pression of some proliferation parameters of mono- 
nuclear leucocytes after in vivo administration fmethyl- 
prednisolone, while the in vitro effects of dexamethasone 
appear to be normal. These findings together with re- 
cently reported alterations in glucocorticoid receptor 
pharmacology in AD [27] suggest a decreased biological 
efficiency of methylprednisolone on lymphocytes in vivo, 
the origin of which remains to be elucidated. 
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